RAD51 as a biomarker for homologous recombination deficiency in high-grade serous ovarian carcinoma: robustness and interobserver variability of the RAD51 test.

MLA

Kramer, Claire Jh, et al. “RAD51 as a Biomarker for Homologous Recombination Deficiency in High-Grade Serous Ovarian Carcinoma: Robustness and Interobserver Variability of the RAD51 Test.” The Journal of Pathology. Clinical Research, vol. 9, no. 6, Nov. 2023, pp. 442–48. EBSCOhost, https://doi.org/10.1002/cjp2.336.

APA

Kramer, C. J., Llop-Guevara, A., Yaniz-Galende, E., Pellegrino, B., Ter Haar, N. T., Herencia-Ropero, A., Campanini, N., Musolino, A., Bosse, T., Leary, A., Serra, V., & Vreeswijk, M. P. (2023). RAD51 as a biomarker for homologous recombination deficiency in high-grade serous ovarian carcinoma: robustness and interobserver variability of the RAD51 test. The Journal of Pathology. Clinical Research, 9(6), 442–448. https://doi.org/10.1002/cjp2.336

Chicago

Kramer, Claire Jh, Alba Llop-Guevara, Elisa Yaniz-Galende, Benedetta Pellegrino, Natalja T Ter Haar, Andrea Herencia-Ropero, Nicoletta Campanini, et al. 2023. “RAD51 as a Biomarker for Homologous Recombination Deficiency in High-Grade Serous Ovarian Carcinoma: Robustness and Interobserver Variability of the RAD51 Test.” The Journal of Pathology. Clinical Research 9 (6): 442–48. doi:10.1002/cjp2.336.